【Destiny Pharma-Product XF-73】Destiny Pharma Appoints MedPharm to Develop New XF-platform Drug Formulations

Partner News

27th March
2019– Destiny Pharma issued an announcement, which is summarized as

Destiny Pharma is
pleased to announce that it has appointed MedPharm as its expert partner to
develop new topical formulations of the Company’s novel XF-platform compounds.
These new treatments for dermal and ocular infections are part of its second
clinical programme to address the global problem of anti-microbial resistance
(AMR). MedPharm is a world
 leading contract provider of topical
and transdermal product design and formulation development services using
sophisticated in vitro models to de-risk development

MedPharm will develop
new formulations containing Destiny Pharma’s XF-platform compounds for the
treatment of a number of topically treated infections, including diabetic foot
ulcers and ophthalmic infections. 

Original website Link: